Phase 1 Placeholder

This is a placeholder. It's hidden from the grid/chart , but necessary to display the filter option until real projects have this category. Keep the category "Hidden"...

RAF / KIN-2787

In our lead program, we are developing small molecule kinase inhibitors targeting specific classes of BRAF kinase mutations (Class II and Class III BRAF mutations) that characterize subsets of melanoma, lung cancer and other solid tumors. While three BRAF targeted...